The global wegovy market size is calculated at USD 3.07 billion in 2025 and is forecasted to reach around USD 24.53 billion by 2034, accelerating at a CAGR of 25.96% from 2025 to 2034. The North America market size surpassed USD 1.17 billion in 2024 and is expanding at a CAGR of 26.11% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Pricing Tiers
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introductiohn
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Eleven Analysis
4.3.3. Downstream Buyer Analysis
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
7.1. Wegovy Market Revenue and Volume, by Drug Type
7.1.1. Branded Semaglutide
7.1.1.1. Market Revenue and Volume Forecast
7.1.2. Generic/Biosimilar Semaglutide
7.1.2.1. Market Revenue and Volume Forecast
8.1. Wegovy Market Revenue and Volume, by Route of Administration
8.1.1. Subcutaneous Injection
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Oral Formulations
8.1.2.1. Market Revenue and Volume Forecast
9.1. Wegovy Market Revenue and Volume, by Dosage Strength
9.1.1. 0.25 mg/week
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. 0.5 mg/week
9.1.2.1. Market Revenue and Volume Forecast
9.1.2. 1 mg/week
9.1.2.1. Market Revenue and Volume Forecast
9.1.2. 1.7 mg/week
9.1.2.1. Market Revenue and Volume Forecast
9.1.2. 2.4 mg/week
9.1.2.1. Market Revenue and Volume Forecast
10.1. Wegovy Market Revenue and Volume, by Patient Demographics
10.1.1. Bottles
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Adults (18–65 years)
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Elderly (>65 years)
10.1.3.1. Market Revenue and Volume Forecast
10.1.4. Adolescents (12–17 years)
10.1.4.1. Market Revenue and Volume Forecast
11.1. Wegovy Market Revenue and Volume, by BMI Category
11.1.1. BMI 27–29.9 (Overweight, with comorbidity)
11.1.1.1. Market Revenue and Volume Forecast
11.1.2. BMI ≥30 (Obese)
11.1.2.1. Market Revenue and Volume Forecast
12.1. Wegovy Market Revenue and Volume, by Distribution Channel
12.1.1. Retail Pharmacies
12.1.1.1. Market Revenue and Volume Forecast
12.1.2. Hospital Pharmacies
12.1.2.1. Market Revenue and Volume Forecast
12.1.3. Online Pharmacies
12.1.3.1. Market Revenue and Volume Forecast
12.1.4. Specialty Clinics
12.1.4.1. Market Revenue and Volume Forecast
13.1. Wegovy Market Revenue and Volume, by Application/Indication
13.1.1. Obesity Management
13.1.1.1. Market Revenue and Volume Forecast
13.1.2. Type 2 Diabetes with Obesity
13.1.2.1. Market Revenue and Volume Forecast
13.1.3. Cardiovascular Risk Reduction
13.1.3.1. Market Revenue and Volume Forecast
13.1.4. Metabolic Syndrome
13.1.4.1. Market Revenue and Volume Forecast
14.1. Wegovy Market Revenue and Volume, by End User
14.1.1. Hospitals
14.1.1.1. Market Revenue and Volume Forecast
14.1.2. Ambulatory Surgical Centers (ASCs)
14.1.2.1. Market Revenue and Volume Forecast
14.1.3. Weight Management Clinics
14.1.3.1. Market Revenue and Volume Forecast
14.1.4. Home Care Settings
14.1.4.1. Market Revenue and Volume Forecast
15.1. Wegovy Market Revenue and Volume, by Pricing Tier
15.1.1. High-Income Market (Cash Pay or Reimbursed)
15.1.1.1. Market Revenue and Volume Forecast
15.1.2. Middle-Income Market (Insurance Dependent)
15.1.2.1. Market Revenue and Volume Forecast
15.1.3. Home Care Settings
15.1.3.1. Market Revenue and Volume Forecast
16.1. North America
16.1.1. Market Revenue and Volume Forecast, by Drug Type
16.1.2. Market Revenue and Volume Forecast, by Route of Administration
16.1.3. Market Revenue and Volume Forecast, by Dosage Strength
16.1.4. Market Revenue and Volume Forecast, by Patient Demographics
16.1.5. Market Revenue and Volume Forecast, by BMI Category
16.1.6. Market Revenue and Volume Forecast, by Application/Indication
16.1.7. Market Revenue and Volume Forecast, by Distribution Channel
16.1.8. Market Revenue and Volume Forecast, by End User
16.1.9. Market Revenue and Volume Forecast, by Pricing Tier
16.1.10. U.S.
16.1.10.1. Market Revenue and Volume Forecast, by Drug Type
16.1.10.2. Market Revenue and Volume Forecast, by Route of Administration
16.1.10.3. Market Revenue and Volume Forecast, by Dosage Strength
16.1.10.4. Market Revenue and Volume Forecast, by Patient Demographics
16.1.10.5. Market Revenue and Volume Forecast, by BMI Category
16.1.10.6. Market Revenue and Volume Forecast, by Application/Indication
16.1.10.7. Market Revenue and Volume Forecast, by Distribution Channel
16.1.10.8. Market Revenue and Volume Forecast, by End User
16.1.10.9. Market Revenue and Volume Forecast, by Pricing Tier
16.1.11. Rest of North America
16.1.11.1. Market Revenue and Volume Forecast, by Drug Type
16.1.11.2. Market Revenue and Volume Forecast, by Route of Administration
16.1.11.3. Market Revenue and Volume Forecast, by Dosage Strength
16.1.11.4. Market Revenue and Volume Forecast, by Patient Demographics
16.1.11.5. Market Revenue and Volume Forecast, by BMI Category
16.1.11.6. Market Revenue and Volume Forecast, by Application/Indication
16.1.11.7. Market Revenue and Volume Forecast, by Distribution Channel
16.1.11.8. Market Revenue and Volume Forecast, by End User
16.1.11.9. Market Revenue and Volume Forecast, by Pricing Tier
16.2. Europe
16.2.1. Market Revenue and Volume Forecast, by Drug Type
16.2.2. Market Revenue and Volume Forecast, by Route of Administration
16.2.3. Market Revenue and Volume Forecast, by Dosage Strength
16.2.4. Market Revenue and Volume Forecast, by Patient Demographics
16.2.5. Market Revenue and Volume Forecast, by BMI Category
16.2.6. Market Revenue and Volume Forecast, by Application/Indication
16.2.7. Market Revenue and Volume Forecast, by Distribution Channel
16.2.8. Market Revenue and Volume Forecast, by End User
16.2.9. Market Revenue and Volume Forecast, by Pricing Tier
16.2.10. UK
16.2.10.1. Market Revenue and Volume Forecast, by Drug Type
16.2.10.2. Market Revenue and Volume Forecast, by Route of Administration
16.2.10.3. Market Revenue and Volume Forecast, by Dosage Strength
16.2.10.4. Market Revenue and Volume Forecast, by Patient Demographics
16.2.10.5. Market Revenue and Volume Forecast, by BMI Category
16.2.10.6. Market Revenue and Volume Forecast, by Application/Indication
16.2.10.7. Market Revenue and Volume Forecast, by Distribution Channel
16.2.10.8. Market Revenue and Volume Forecast, by End User
16.2.10.9. Market Revenue and Volume Forecast, by Pricing Tier
16.2.11. Germany
16.2.11.1. Market Revenue and Volume Forecast, by Drug Type
16.2.11.2. Market Revenue and Volume Forecast, by Route of Administration
16.2.11.3. Market Revenue and Volume Forecast, by Dosage Strength
16.2.11.4. Market Revenue and Volume Forecast, by Patient Demographics
16.2.11.5. Market Revenue and Volume Forecast, by BMI Category
16.2.11.6. Market Revenue and Volume Forecast, by Application/Indication
16.2.11.7. Market Revenue and Volume Forecast, by Distribution Channel
16.2.11.8. Market Revenue and Volume Forecast, by End User
16.2.11.9. Market Revenue and Volume Forecast, by Pricing Tier
16.2.12. France
16.2.12.1. Market Revenue and Volume Forecast, by Drug Type
16.2.12.2. Market Revenue and Volume Forecast, by Route of Administration
16.2.12.3. Market Revenue and Volume Forecast, by Dosage Strength
16.2.12.4. Market Revenue and Volume Forecast, by Patient Demographics
16.2.12.5. Market Revenue and Volume Forecast, by BMI Category
16.2.12.6. Market Revenue and Volume Forecast, by Application/Indication
16.2.12.7. Market Revenue and Volume Forecast, by Distribution Channel
16.2.12.8. Market Revenue and Volume Forecast, by End User
16.2.12.9. Market Revenue and Volume Forecast, by Pricing Tier
16.2.13. Rest of Europe
16.2.13.1. Market Revenue and Volume Forecast, by Drug Type
16.2.13.2. Market Revenue and Volume Forecast, by Route of Administration
16.2.13.3. Market Revenue and Volume Forecast, by Dosage Strength
16.2.13.4. Market Revenue and Volume Forecast, by Patient Demographics
16.2.13.5. Market Revenue and Volume Forecast, by BMI Category
16.2.13.6. Market Revenue and Volume Forecast, by Application/Indication
16.2.13.7. Market Revenue and Volume Forecast, by Distribution Channel
16.2.13.8. Market Revenue and Volume Forecast, by End User
16.2.13.9. Market Revenue and Volume Forecast, by Pricing Tier
16.3. APAC
16.3.1. Market Revenue and Volume Forecast, by Drug Type
16.3.2. Market Revenue and Volume Forecast, by Route of Administration
16.3.3. Market Revenue and Volume Forecast, by Dosage Strength
16.3.4. Market Revenue and Volume Forecast, by Patient Demographics
16.3.5. Market Revenue and Volume Forecast, by BMI Category
16.3.6. Market Revenue and Volume Forecast, by Application/Indication
16.3.7. Market Revenue and Volume Forecast, by Distribution Channel
16.3.8. Market Revenue and Volume Forecast, by End User
16.3.9. Market Revenue and Volume Forecast, by Pricing Tier
16.3.10. India
16.3.10.1. Market Revenue and Volume Forecast, by Drug Type
16.3.10.2. Market Revenue and Volume Forecast, by Route of Administration
16.3.10.3. Market Revenue and Volume Forecast, by Dosage Strength
16.3.10.4. Market Revenue and Volume Forecast, by Patient Demographics
16.3.10.5. Market Revenue and Volume Forecast, by BMI Category
16.3.10.6. Market Revenue and Volume Forecast, by Application/Indication
16.3.10.7. Market Revenue and Volume Forecast, by Distribution Channel
16.3.10.8. Market Revenue and Volume Forecast, by End User
16.3.10.9. Market Revenue and Volume Forecast, by Pricing Tier
16.3.11. China
16.3.11.1. Market Revenue and Volume Forecast, by Drug Type
16.3.11.2. Market Revenue and Volume Forecast, by Route of Administration
16.3.11.3. Market Revenue and Volume Forecast, by Dosage Strength
16.3.11.4. Market Revenue and Volume Forecast, by Patient Demographics
16.3.11.5. Market Revenue and Volume Forecast, by BMI Category
16.3.11.6. Market Revenue and Volume Forecast, by Application/Indication
16.3.11.7. Market Revenue and Volume Forecast, by Distribution Channel
16.3.11.8. Market Revenue and Volume Forecast, by End User
16.3.11.9. Market Revenue and Volume Forecast, by Pricing Tier
16.3.12. Japan
16.3.12.1. Market Revenue and Volume Forecast, by Drug Type
16.3.12.2. Market Revenue and Volume Forecast, by Route of Administration
16.3.12.3. Market Revenue and Volume Forecast, by Dosage Strength
16.3.12.4. Market Revenue and Volume Forecast, by Patient Demographics
16.3.12.5. Market Revenue and Volume Forecast, by BMI Category
16.3.12.6. Market Revenue and Volume Forecast, by Application/Indication
16.3.12.7. Market Revenue and Volume Forecast, by Distribution Channel
16.3.12.8. Market Revenue and Volume Forecast, by End User
16.3.12.9. Market Revenue and Volume Forecast, by Pricing Tier
16.3.13. Rest of APAC
16.3.13.1. Market Revenue and Volume Forecast, by Drug Type
16.3.13.2. Market Revenue and Volume Forecast, by Route of Administration
16.3.13.3. Market Revenue and Volume Forecast, by Dosage Strength
16.3.13.4. Market Revenue and Volume Forecast, by Patient Demographics
16.3.13.5. Market Revenue and Volume Forecast, by BMI Category
16.3.13.6. Market Revenue and Volume Forecast, by Application/Indication
16.3.13.7. Market Revenue and Volume Forecast, by Distribution Channel
16.3.13.8. Market Revenue and Volume Forecast, by End User
16.3.13.9. Market Revenue and Volume Forecast, by Pricing Tier
16.4. MEA
16.4.1. Market Revenue and Volume Forecast, by Drug Type
16.4.2. Market Revenue and Volume Forecast, by Route of Administration
16.4.3. Market Revenue and Volume Forecast, by Dosage Strength
16.4.4. Market Revenue and Volume Forecast, by Patient Demographics
16.4.5. Market Revenue and Volume Forecast, by BMI Category
16.4.6. Market Revenue and Volume Forecast, by Application/Indication
16.4.7. Market Revenue and Volume Forecast, by Distribution Channel
16.4.8. Market Revenue and Volume Forecast, by End User
16.4.9. Market Revenue and Volume Forecast, by Pricing Tier
16.4.10. GCC
16.4.10.1. Market Revenue and Volume Forecast, by Drug Type
16.4.10.2. Market Revenue and Volume Forecast, by Route of Administration
16.4.10.3. Market Revenue and Volume Forecast, by Dosage Strength
16.4.10.4. Market Revenue and Volume Forecast, by Patient Demographics
16.4.10.5. Market Revenue and Volume Forecast, by BMI Category
16.4.10.6. Market Revenue and Volume Forecast, by Application/Indication
16.4.10.7. Market Revenue and Volume Forecast, by Distribution Channel
16.4.10.8. Market Revenue and Volume Forecast, by End User
16.4.10.9. Market Revenue and Volume Forecast, by Pricing Tier
16.4.11. North Africa
16.4.11.1. Market Revenue and Volume Forecast, by Drug Type
16.4.11.2. Market Revenue and Volume Forecast, by Route of Administration
16.4.11.3. Market Revenue and Volume Forecast, by Dosage Strength
16.4.11.4. Market Revenue and Volume Forecast, by Patient Demographics
16.4.11.5. Market Revenue and Volume Forecast, by BMI Category
16.4.11.6. Market Revenue and Volume Forecast, by Application/Indication
16.4.11.7. Market Revenue and Volume Forecast, by Distribution Channel
16.4.11.8. Market Revenue and Volume Forecast, by End User
16.4.11.9. Market Revenue and Volume Forecast, by Pricing Tier
16.4.12. South Africa
16.4.12.1. Market Revenue and Volume Forecast, by Drug Type
16.4.12.2. Market Revenue and Volume Forecast, by Route of Administration
16.4.12.3. Market Revenue and Volume Forecast, by Dosage Strength
16.4.12.4. Market Revenue and Volume Forecast, by Patient Demographics
16.4.12.5. Market Revenue and Volume Forecast, by BMI Category
16.4.12.6. Market Revenue and Volume Forecast, by Application/Indication
16.4.12.7. Market Revenue and Volume Forecast, by Distribution Channel
16.4.12.8. Market Revenue and Volume Forecast, by End User
16.4.12.9. Market Revenue and Volume Forecast, by Pricing Tier
16.4.13. Rest of MEA
16.4.13.1. Market Revenue and Volume Forecast, by Drug Type
16.4.13.2. Market Revenue and Volume Forecast, by Route of Administration
16.4.13.3. Market Revenue and Volume Forecast, by Dosage Strength
16.4.13.4. Market Revenue and Volume Forecast, by Patient Demographics
16.4.13.5. Market Revenue and Volume Forecast, by BMI Category
16.4.13.6. Market Revenue and Volume Forecast, by Application/Indication
16.4.13.7. Market Revenue and Volume Forecast, by Distribution Channel
16.4.13.8. Market Revenue and Volume Forecast, by End User
16.4.13.9. Market Revenue and Volume Forecast, by Pricing Tier
16.5. Latin America
16.5.1. Market Revenue and Volume Forecast, by Drug Type
16.5.2. Market Revenue and Volume Forecast, by Route of Administration
16.5.3. Market Revenue and Volume Forecast, by Dosage Strength
16.5.4. Market Revenue and Volume Forecast, by Patient Demographics
16.5.5. Market Revenue and Volume Forecast, by BMI Category
16.5.6. Market Revenue and Volume Forecast, by Application/Indication
16.5.7. Market Revenue and Volume Forecast, by Distribution Channel
16.5.8. Market Revenue and Volume Forecast, by End User
16.5.9. Market Revenue and Volume Forecast, by Pricing Tier
16.5.10. Brazil
16.5.10.1. Market Revenue and Volume Forecast, by Drug Type
16.5.10.2. Market Revenue and Volume Forecast, by Route of Administration
16.5.10.3. Market Revenue and Volume Forecast, by Dosage Strength
16.5.10.4. Market Revenue and Volume Forecast, by Patient Demographics
16.5.10.5. Market Revenue and Volume Forecast, by BMI Category
16.5.10.6. Market Revenue and Volume Forecast, by Application/Indication
16.5.10.7. Market Revenue and Volume Forecast, by Distribution Channel
16.5.10.8. Market Revenue and Volume Forecast, by End User
16.5.10.9. Market Revenue and Volume Forecast, by Pricing Tier
16.5.11. Rest of LATAM
16.5.11.1. Market Revenue and Volume Forecast, by Drug Type
16.5.11.2. Market Revenue and Volume Forecast, by Route of Administration
16.5.11.3. Market Revenue and Volume Forecast, by Dosage Strength
16.5.11.4. Market Revenue and Volume Forecast, by Patient Demographics
16.5.11.5. Market Revenue and Volume Forecast, by BMI Category
16.5.11.6. Market Revenue and Volume Forecast, by Application/Indication
16.5.11.7. Market Revenue and Volume Forecast, by Distribution Channel
16.5.11.8. Market Revenue and Volume Forecast, by End User
16.5.11.9. Market Revenue and Volume Forecast, by Pricing Tier
17.1. Sanofi S.A.
17.1.1. Company Overview
17.1.2. Product Offerings
17.1.3. Financial Performance
17.1.4. Recent Initiatives
17.2. AstraZeneca plc
17.2.1. Company Overview
17.2.2. Product Offerings
17.2.3. Financial Performance
17.2.4. Recent Initiatives
17.3. Innovent Biologics
17.3.1. Company Overview
17.3.2. Product Offerings
17.3.3. Financial Performance
17.3.4. Recent Initiatives
17.4. Zealand Pharma
17.4.1. Company Overview
17.4.2. Product Offerings
17.4.3. Financial Performance
17.4.4. Recent Initiatives
17.5. Gubra ApS
17.5.1. Company Overview
17.5.2. Product Offerings
17.5.3. Financial Performance
17.5.4. Recent Initiatives
17.6. BioAge Labs
17.6.1. Company Overview
17.6.2. Product Offerings
17.6.3. Financial Performance
17.6.4. Recent Initiatives
17.7. Sciwind Biosciences
17.7.1. Company Overview
17.7.2. Product Offerings
17.7.3. Financial Performance
17.7.4. Recent Initiatives
17.8. Terns Pharmaceuticals
17.8.1. Company Overview
17.8.2. Product Offerings
17.8.3. Financial Performance
17.8.4. Recent Initiatives
17.9. China Meheco
17.9.1. Company Overview
17.9.2. Product Offerings
17.9.3. Financial Performance
17.9.4. Recent Initiatives
17.11. Pfizer Inc. – Pipeline oral GLP-1s
17.11.1. Company Overview
17.11.2. Product Offerings
17.11.3. Financial Performance
17.11.4. Recent Initiatives
18.1. Primary Research
18.2. Secondary Research
18.3. Assumptions
19.1. About Us
19.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description